Artivion, Inc. (AORT)

US — Healthcare Sector
Peers: ANIK  SGHT  OFIX  AVNS  AXGN  LUNG  ELMD  SRDX  NUVA  CNMD  KIDS  SIBN  NPCE  CVRX  HSKA  ITGR  TMCI  ESTA 

Automate Your Wheel Strategy on AORT

With Tiblio's Option Bot, you can configure your own wheel strategy including AORT - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol AORT
  • Rev/Share 9.2367
  • Book/Share 6.9675
  • PB 4.2641
  • Debt/Equity 1.2315
  • CurrentRatio 5.5313
  • ROIC 0.02

 

  • MktCap 1268700188.0
  • FreeCF/Share 0.0501
  • PFCF 600.142
  • PE -58.6397
  • Debt/Assets 0.458
  • DivYield 0
  • ROE -0.0731

 

  • Rating D+
  • Score 1
  • Recommendation Strong Sell
  • P/E Score 1
  • DCF Score 1
  • P/B Score 2
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Initiation AORT JMP Securities -- Mkt Outperform -- $33 Oct. 23, 2024

News

Artivion, Inc. (AORT) Q1 2025 Earnings Call Transcript
AORT
Published: May 05, 2025 by: Seeking Alpha
Sentiment: Neutral

Artivion, Inc. (NYSE:AORT ) Q1 2025 Earnings Conference Call May 5, 2025 4:30 PM ET Company Participants Dorothy Morgan - Gilmartin Group LLC Pat Mackin - Chief Executive Officer Lance Berry - Chief Financial Officer Conference Call Participants John McAulay - Stifel Frank Takkinen - Lake Street Capital Markets Suraj Kalia - Oppenheimer & Company Mike Matson - Needham & Company Daniel Stauter - Citizens Jeffrey Cohen - Ladenburg Thalmann Operator Greetings. Welcome to Artivion's First Quarter 2025 Financial Conference Call.

Read More
image for news Artivion, Inc. (AORT) Q1 2025 Earnings Call Transcript
Artivion, Inc. (AORT) Q4 2024 Earnings Call Transcript
AORT
Published: February 24, 2025 by: Seeking Alpha
Sentiment: Neutral

Artivion, Inc. (NYSE:AORT ) Q4 2024 Earnings Conference Call February 24, 2025 4:30 PM ET Company Participants Dorothy Morgan - Gilmartin Group LLC Pat Mackin - Chief Executive Officer Lance Berry - Chief Financial Officer Conference Call Participants Rick Wise - Stifel Frank Takkinen - Lake Street Capital Markets Suraj Kalia - Oppenheimer & Company Mike Matson - Needham & Company Daniel Stauter - Citizens Jeffrey Cohen - Ladenburg Thalmann Operator Greetings, and welcome to the Artivion Fourth Quarter and Year End 2024 Financial Conference Call. [Operator Instructions] As a reminder, this conference is being recorded.

Read More
image for news Artivion, Inc. (AORT) Q4 2024 Earnings Call Transcript

About Artivion, Inc. (AORT)

  • IPO Date 1993-02-12
  • Website https://artivion.com
  • Industry Medical - Devices
  • CEO Mr. James Patrick Mackin
  • Employees 1600
Artivion Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company offers BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and E-vita Open Plus and E-vita Open Neo. It also provides E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G for the endovascular treatment of thoracic aortic aneurysms; E-nya, a thoracic stent graft system for the minimally invasive repair of lesions of the descending aorta; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries, and aneurysmal iliac side branches; and E-tegra, an abdominal aortic aneurysms stent graft system. In addition, the company offers synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; cardiac laser therapy products for angina treatment; CryoVein femoral vein and CryoArtery femoral artery vascular preservation services; On-X prosthetic aortic and mitral heart valves and the On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures for mitral chordal replacement; and ascyrus medical dissection stents, as well as pyrolytic carbon coating services to medical device manufacturers. It serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons. The company was formerly known as CryoLife, Inc. and changed its name to Artivion Inc. in January 2022. The company was founded in 1984 and is headquartered in Kennesaw, Georgia.